PubRank

In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth.

PubWeight™: 0.88‹?›

🔗 View Article (PMID 25065596)

Published in Oncogene on July 28, 2014

Authors

N Jiang1, K Hjorth-Jensen2, O Hekmat2, D Iglesias-Gato2, T Kruse2, C Wang3, W Wei3, B Ke3, B Yan3, Y Niu3, J V Olsen2, A Flores-Morales2

Author Affiliations

1: 1] The Novo Nordisk Foundation Center for Protein Research, Department of Health Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark [2] Tianjin Institute of Urology, Tianjin Medical University, Tianjin, China.
2: The Novo Nordisk Foundation Center for Protein Research, Department of Health Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
3: Tianjin Institute of Urology, Tianjin Medical University, Tianjin, China.

Articles citing this ↘

Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal (2015) 1.52

OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer (2015) 1.47

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene (2015) 0.96

Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget (2015) 0.85

YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells. Onco Targets Ther (2016) 0.83

Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther (2016) 0.81

YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun (2015) 0.75